SWOG clinical trial number
SWOG-9307

Extended Administration of Oral Etoposide And Oral Cyclophosphamide for the Treatment of Poor Prognosis Extensive Disease Small Cell Lung Cancer, Phase II Pilot

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Extended Administration of Oral Etoposide And Oral Cyclophosphamide for the Treatment of Poor Prognosis Extensive Disease Small Cell Lung Cancer, Phase II Pilot
Activated
07/01/1993
Closed
06/01/1996

Research committees

Lung Cancer

Publication Information Expand/Collapse

1999

Treatment of poor prognosis extensive disease small cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - A Southwest Oncology Group clinical and pharmacokinetic study.

SM Grunberg;JJ Crowley;KR Hande;DJ Giroux;NC Munshi;DHM Lau;LE Schroder;MH Zangmeister;SP Balcerzak;HE Hynes;DR Gandara Cancer Chemotherapy and Pharmacology 44:461-468

1997

Oral etoposide (VP) and oral cyclophosphamide (CP) for poor prognosis extensive disease (ED) small cell lung cancer (SCLC). A Southwest Oncology Group clinical and pharmacokinetic study.

SM Grunberg;D Rector;K Hande;R Livingston Lung Cancer 18(Suppl.1)(#85):24-25

1994

Extended oral etopside (E) and oral cyclophosphamide (C) for lung cancer

SM Grunberg;J Crowley;R Livingston Lung Cancer 11(Suppl.1):121(#464)

Other Clinical Trials

SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Management and Survivorship
Activated
03/14/2025
Accrual
2%
Open
Phase